1. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection 
Johannes Vermehren, James S. Park, Ira M. Jacobson, Stefan Zeuzem 
Journal of Hepatology 
Volume 69, Issue 5, Pages (November 2018)
DOI: /j.jhep
Copyright © Terms and Conditions

2. Fig. 1
Antiviral treatment algorithm in challenging HCV cases. Recently introduced pangenotypic regimens have addressed critical remaining gaps in the capacity to treat challenging populations with HCV infection. See text and tables for indications and recommendations, including variations in regulatory approvals and expert guidelines, in specific subgroups, e.g. treatment-naive vs. experienced, non-cirrhotics vs. cirrhotics, baseline resistance-associated substitutions (RAS), and DAA failures. DAA, direct-acting antiviral; EBR/GZR, elbasvir/grazoprevir; G/P, glecaprevir/pibrentasvir; GT, genotype; HCV, hepatitis C virus; NS3 exp., patients with prior HCV NS3/4A protease inhibitor failure; NS5A exp., patients with prior HCV NS5A-inhibitor failure; P/R exp., patients with prior pegylated interferon and ribavirin failure; SOF/LDV, sofosbuvir/ledipasvir; SOF/VEL, sofosbuvir/velpatasvir; SOF/VEL/VOX, sofosbuvir/velpatasvir/voxilaprevir; RBV, ribavirin.
Journal of Hepatology  , DOI: ( /j.jhep )
Copyright © Terms and Conditions